Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Oncology

• Publication date

  2017-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/ijo.2017.4147PMID 29039611
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.

  2016cited by this paper
• A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.

  2016cited by this paper
• Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells

  2016cited by this paper
• Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection

  2016cited by this paper
• Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown

  2016cited by this paper
• GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy

  2016cited by this paper
• Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4.

  2016cited by this paper
• Role of N-acetylgalactosaminyltransferase 6 in early tumorigenesis and formation of metastasis.

  2016cited by this paper
• Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation

  2016cited by this paper
• GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells

  2015cited by this paper
• Glycosyltransferases as marker genes for the quantitative polymerase chain reaction-based detection of circulating tumour cells from blood samples of patients with breast cancer undergoing adjuvant therapy.

  2015cited by this paper
• Protein glycosylation in cancer.

  2015cited by this paper
• GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma

  2015cited by this paper
• GALNT14 mediates tumor invasion and migration in breast cancer cell MCF‐7

  2015cited by this paper
• Glycosylation in cancer: mechanisms and clinical implications

  2015cited by this paper
• The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain

  2015cited by this paper
• Cell surface protein glycosylation in cancer

  2014cited by this paper
• The extended ppGalNAc-T family and their functional involvement in the metastatic cascade.

  2014cited by this paper
• GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma

  2014cited by this paper
• GALNT4 predicts clinical outcome in patients with clear cell renal cell carcinoma.

  2014cited by this paper
• Identification of 33 candidate oncogenes by screening for base-specific mutations

  2014cited by this paper
• Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation

  2014cited by this paper
• Role of aberrant glycosylation in ovarian cancer dissemination

  2014cited by this paper
• GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.

  2014cited by this paper
• GALNT9 gene expression is a prognostic marker in neuroblastoma patients.

  2013cited by this paper
• Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series.

  2013cited by this paper
• Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas

  2013cited by this paper
• The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.

  2013cited by this paper
• Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.

  2013cited by this paper
• Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family.

  2012cited by this paper
• Management of ovarian cancer has changed.

  2012cited by this paper
• ZNF385B and VEGFA Are Strongly Differentially Expressed in Serous Ovarian Carcinomas and Correlate with Survival

  2012cited by this paper
• Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival

  2011cited by this paper
• Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.

  2011cited by this paper
• GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.

  2011cited by this paper
• Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin.

  2011cited by this paper
• Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process

  2011cited by this paper
• Cancer statistics, 2011

  2011cited by this paper
• Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

  2011cited by this paper
• Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis.

  2010cited by this paper
• Glycomic analysis of ovarian cancer: Past, present, and future

  2010cited by this paper
• The role of mucin-type O-glycans in eukaryotic development.

  2010cited by this paper
• N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry

  2010cited by this paper
• GalNAc-T14 may be involved in regulating the apoptotic action of IGFBP-3

  2009cited by this paper
• Expression of UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 in Gastric Mucosa, Intestinal Metaplasia, and Gastric Carcinoma

  2009cited by this paper
• Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells.

  2009cited by this paper
• TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

  2008cited by this paper
• Prognostic utility of glycosyltransferase expression in breast cancer.

  2008cited by this paper
• Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer.

  2007cited by this paper
• Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

  2007cited by this paper
• UDP-N-Acetyl-d-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker

  2006cited by this paper
• UDP‐N‐acetyl‐D‐galactosamine:polypeptide N‐acetylgalactosaminyltransferase 6 (ppGalNAc‐T6) mRNA as a potential new marker for detection of bone marrow‐disseminated breast cancer cells

  2006cited by this paper
• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

  2005cited by this paper
• The Chemistry and Biology of Mucin‐Type O‐Linked Glycosylation

  2005cited by this paper
• The chemistry and biology of mucin-type O-linked glycosylation.

  2005cited by this paper
• The sweet and sour of cancer: glycans as novel therapeutic targets

  2005cited by this paper
• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

  2005cited by this paper
• Comment on : New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Author's reply

  2005cited by this paper
• Glycans in cancer and inflammation — potential for therapeutics and diagnostics

  2005cited by this paper
• All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.

  2003cited by this paper
• Glycosylation defining cancer malignancy: New wine in an old bottle

  2002cited by this paper
• [Management of ovarian cancer].

  2001cited by this paper
• Cloning and Characterization of a Close Homologue of Human UDP-N-acetyl-α-d-galactosamine:Polypeptide N-Acetylgalactosaminyltransferase-T3, Designated GalNAc-T6

  1999cited by this paper
• Cloning of a Human UDP-N-Acetyl-α-d-Galactosamine:PolypeptideN-Acetylgalactosaminyltransferase That Complements Other GalNAc-Transferases in Complete O-Glycosylation of the MUC1 Tandem Repeat*

  1998cited by this paper
• Complexity in O-linked oligosaccharide biosynthesis engendered by multiple polypeptide N-acetylgalactosaminyltransferases.

  1996cited by this paper
• Cancer statistics

  1989cited by this paper

• Identification and validation of glycosyltransferase-related gene signatures to predict prognosis and immunological characteristics of renal clear cell carcinoma

  2025cites this paper
• O‐GalNAc Glycosylation Activates MBL‐Mediated Complement and Coagulation Cascades to Drive Organotropic Metastasis

  2025cites this paper
• GALNT3 is a novel target driving lymphomagenesis via O-glycosylation of FGFR2

  2025cites this paper
• Pan-Cancer Analysis of GALNT6 with Potential Implications for Prognosis and Tumor Microenvironment in Human Cancer Based on Bioinformatics and qPCR Verification

  2024cites this paper
• The emerging role of Fusobacteria in carcinogenesis

  2024cites this paper
• GALNT2 targeted by miR-139-5p promotes proliferation of clear cell renal cell carcinoma via inhibition of LATS2 activation

  2024cites this paper
• Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects

  2024cites this paper
• Increased Expression of the Pathological O-glycosylated Form of Oncofetal Fibronectin in the Multidrug Resistance Phenotype of Cancer Cells.

  2023cites this paper
• Downregulation of circ_0119412 expression inhibits malignant progression of breast cancer by targeting the miR-1205/GALNT6 pathway in vivo and in vitro

  2023cites this paper
• Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer

  2023cites this paper
• Meta‐analysis of microarray data to determine gene indicators involved in the cisplatin resistance in ovarian cancer

  2023cites this paper
• The EMT-Related Genes GALNT3 and OAS1 are Associated with Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma.

  2023cites this paper
• Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma

  2023cites this paper
• Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) as a Chemosensitivity-Related Biomarker for Osteosarcoma

  2023cites this paper
• Early-Stage Loss of GALNT6 Predicts Poor Clinical Outcome in Colorectal Cancer

  2022cites this paper
• Pan‐cancer analysis of GALNTs expression identifies a prognostic of GALNTs feature in low grade glioma

  2022cites this paper
• Protein Glycosylation as Biomarkers in Gynecologic Cancers

  2022cites this paper
• Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

  2021cites this paper
• LncRNA PSMA3‐AS1 promotes cell proliferation, migration, and invasion in ovarian cancer by activating the PI3K/Akt pathway via the miR‐378a‐3p/GALNT3 axis

  2021influential citation
• Mucin-Type O-GalNAc Glycosylation in Health and Disease.

  2021cites this paper
• Genome‐wide methylomic analyses identify prognostic epigenetic signature in lower grade glioma

  2021cites this paper
• Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL)

  2020cites this paper
• Selectins: An Important Family of Glycan-Binding Cell Adhesion Molecules in Ovarian Cancer

  2020cites this paper
• GalNAc-T3 and MUC1, a combined predictor of prognosis and recurrence in solitary pulmonary adenocarcinoma initially diagnosed as malignant solitary pulmonary nodule (≤ 3 cm)

  2020cites this paper
• GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers

  2020cites this paper
• A seven‐DNA methylation signature as a novel prognostic biomarker in breast cancer

  2020cites this paper
• Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy

  2020cites this paper
• Interactions between tumor mutation burden and immune infiltration in ovarian cancer.

  2020cites this paper
• The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression

  2019cites this paper
• The GALNT6‑LGALS3BP axis promotes breast cancer cell growth.

  2019influential citation
• Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer

  2019cites this paper
• EFEMP2 Mediates GALNT14-Dependent Breast Cancer Cell Invasion

  2018cites this paper